MXPA02003079A - Metodo y composiciones para inhibir la formacion de adhesion. - Google Patents

Metodo y composiciones para inhibir la formacion de adhesion.

Info

Publication number
MXPA02003079A
MXPA02003079A MXPA02003079A MXPA02003079A MXPA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A MX PA02003079 A MXPA02003079 A MX PA02003079A
Authority
MX
Mexico
Prior art keywords
compositions
adhesion formation
inhibiting adhesion
inhibiting
methods
Prior art date
Application number
MXPA02003079A
Other languages
English (en)
Spanish (es)
Inventor
A Cheresh David
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MXPA02003079A publication Critical patent/MXPA02003079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MXPA02003079A 1999-09-23 2000-09-22 Metodo y composiciones para inhibir la formacion de adhesion. MXPA02003079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (1)

Publication Number Publication Date
MXPA02003079A true MXPA02003079A (es) 2004-04-21

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003079A MXPA02003079A (es) 1999-09-23 2000-09-22 Metodo y composiciones para inhibir la formacion de adhesion.

Country Status (9)

Country Link
EP (1) EP1223962A4 (https=)
JP (1) JP2003509468A (https=)
KR (1) KR20020048941A (https=)
CN (1) CN1399554A (https=)
AU (1) AU781442B2 (https=)
BR (1) BR0014222A (https=)
CA (1) CA2384812A1 (https=)
MX (1) MXPA02003079A (https=)
WO (1) WO2001021196A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
EP3485921B1 (en) 2016-07-13 2025-07-23 Mochida Pharmaceutical Co., Ltd. Adhesion-preventing composition
WO2019138583A1 (ja) * 2018-01-15 2019-07-18 持田製薬株式会社 癒着防止用組成物
KR102318958B1 (ko) * 2019-08-08 2021-10-27 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물
EP4126957A4 (en) * 2020-03-31 2024-07-24 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING DYSREGULATED WOUND HEALING

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors

Also Published As

Publication number Publication date
AU781442B2 (en) 2005-05-26
CA2384812A1 (en) 2001-03-29
KR20020048941A (ko) 2002-06-24
AU7985000A (en) 2001-04-24
WO2001021196A1 (en) 2001-03-29
EP1223962A4 (en) 2004-01-21
EP1223962A1 (en) 2002-07-24
BR0014222A (pt) 2003-02-25
CN1399554A (zh) 2003-02-26
JP2003509468A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
MXPA02004671A (es) Conjugados de interferon gamma.
MY122391A (en) Piperazine derivatives as 5-ht1b antagonists
EP1139752A4 (en) TECHNIQUES AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH PROLIFERATIVE CELLS
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
AU2003303598A8 (en) Compositions, methods, and systems for inferring bovine breed
DK0883687T3 (da) C-C CKR-5, CC-chemokinreceptor, derivater deraf og anvendelse deraf
ES2158778A1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
MY124214A (en) Compositions for promoting crowth
HUP0102477A3 (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases and pharmaceutical compositions containing the compounds
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
ES2162676T3 (es) Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
BG103286A (en) Compositions and methods for ore dressing
IL152111A0 (en) Tamandarin and didemnin analogs and methods of making and using them
HUP0105302A2 (hu) 2,3,4,5-Tetrahidro-1H-[1,4]benzodiazepin-3-hidroxámsavak mint mátrix metalloproteináz-inhibitorok, alkalmazásuk és eljárás az előállításukra
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
DK1207870T3 (da) Farmaceutiske præparater, der indeholder N-palmitoylethanolamid og anvendelse deraf
PL334345A1 (en) Novel farnesil transferase inhibitors, their production, pharmaceutic compositions containing them and their application in production drugs
IL168646A (en) Antibodies binding to human magic roundabout (mr) and uses thereof for inhibition of angiogenesis